This site is intended for health professionals only

Stryker announces election of new director


Stryker Corporation announced an increase in the size of its Board of Directors to nine and the election of Dr. Roch Doliveux as a director.

Dr. Doliveux has served since 2005 as Chief Executive Officer and Chairman of the Executive  Committee of UCB S.A., a global biopharmaceutical company.

Dr. Doliveux has previously been a Chief Executive Officer of Pierre Fabre Pharmaceuticals and President, Schering-Plough International, a subsidiary of Schering-Plough Corporation.

Dr. Doliveux holds a master’s degree in business from INSEAD, Fontainebleau, France. He also holds a Ph.D. in Veterinary Medicine from Maisons-Alfort, France.

Article continues below this sponsored advert
Cogora InRead Image
Join us at a one-day virtual cardiology event that will allow you to explore the latest advances in cardiovascular care. With the help of an advisory board of cardiology specialists we have put together an agenda tailored to multi-disciplinary teams - each talk is presented by an expert, or panel, who will share knowledge and case studies of relevance

Stephen P. MacMillan, Chairman, President and Chief Executive Officer of Stryker Corporation, said, “Roch brings an outstanding combination of talents and experiences as a globally-minded healthcare  executive with a strong focus on patients and innovation.”

Stryker is one of the world’s leading medical technology companies and is dedicated to helping healthcare  professionals perform their jobs more efficiently while enhancing patient care.

The Company provides  innovative orthopaedic implants as well as state-of-the-art medical and surgical equipment to help people  lead more active and more satisfying lives.

For more information about Stryker, please visit:

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine